Navigation Links
TechAtlas Group Releases Hepatitis C Competitive Landscape Analysis
Date:8/21/2013

BOSTON, Aug. 21, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Hepatitis C (HCV) competitive landscape map. This particular landscape highlights 25 international companies with over 60 drugs and combinations currently on the market and in development.

(Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO )

Topics include:

  • Winning the HCV race
  • Gilead: the one to beat
  • Debate over what is "Good Enough"
  • Other nukes
  • Leading nuke-less regimens
  • Strategic Implications of Worldwide genotype distribution
  • HCV all-oral combination timeline
  • Competitive positioning and rationale for partnerships and M&A

TechAtlas' analysts have evaluated each clinical asset and combination regimen according to the parameters that dictate their commercial competitiveness, including clinical benefit/risk, cost, patient preference, and reimbursement dynamics. For example, all companies are striving to win the HCV race with an all-oral, genotype-1 or pan-genotypic regimen that is convenient (QD), well-tolerated, highly effective (>90% SVR), as short as possible (12 weeks or less), has few drug-drug interactions (DDI), and works well even in patients with subclinical cirrhosis. Such a regimen could be prescribed by primary physicians with little more information than just a confirmation that the patient has HCV and possibly the viral genotype, allowing far more patients to be treated and cured than the current limited bandwidth of specialists allows, not just in the US and Europe but also in China, Egypt, and other countries were HCV is prevalent but where medical care is not as "high-touch". If multiple regimens achieve "optimal" status, or even come close, then the leaders will be at the mercy of followers willing to cut price to gain market share. But there is going to be considerable debate over what is "good enough" such that payors could push for cost-savings without being seen as compromising patient care.

The TechAtlas map graphically presents every HCV-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs and a timeline of upcoming clinical milestones as well as expected earliest sales dates through 2017. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the hepatology and infectious disease community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

TechAtlas Group's current subscribers have reported that their researchers, business development executives, and senior management have used the maps to guide their business development efforts, R&D resource allocation, and competitive positioning.

Some of the 25 companies featured on the TechAtlas HCV landscape include: AbbVie, Achillion, BMS, Boehringer Ingelheim, Enanta, Gilead, GSK, Idenix, Johnson & Johnson, Merck, Novartis, Presidio, Roche, Scynexis and Vertex.  

For further information on obtaining a copy of this report through an annual subscription, please consult our website: http://www.techatlasgroup.com/order.html

About TechAtlas Group
TechAtlas Group, LLC brings a novel, multi-dimensional, visually stimulating approach to decision makers who are already flooded with data and information but are seeking context and actionable insight to guide their resource allocation for R&D and commercial activities. Founded in 2011, TechAtlas Group, LLC is headquartered in Boston, MA.  Their large team of PhDs is trained to analyze the viability and commercial competitiveness of a variety of technologies and distill their insights into a visual landscape.  As each field evolves, the maps are updated and issued to subscribers.  The TechAtlas mission is to convey in one dynamic diagram what has conventionally been crammed into a static 100-page report.


'/>"/>
SOURCE TechAtlas Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
2. New Survey: Hispanic Teen Drug Use Significantly Higher Than Other Ethnic Groups, Substance Abuse Becoming Normalized Behavior Among Latino Youth
3. CompuGroup Medical US Announces New Laboratory Information System for the Reference Laboratory, CGM ENDEAVOR
4. Yew Bio-Pharm Group Announces Second-Quarter 2013 Results
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
6. AtlantiCare Heart Heroes group donates Cardiac Science AED to Atlantic City public access defibrillation program
7. Hoosier Oncology Group Selects OnCore to Support Clinical Trials Network
8. Linde Distributor Association, at twenty, is a leading buying group in the U.S.
9. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
10. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
11. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
Breaking Medicine News(10 mins):